Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

David Chang, ASCRS 2021: Antibiotic Prophylaxis – Results from the 2021 ASCRS Member Survey

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Aug 31st 2021

We were delighted to speak with our valued Editorial Board member, David Chang (University of California, San Francisco, CA, USA), about the results of the 2021 ASCRS Member Survey on Antibiotic Prophylaxis.

Questions

  1. In the 2021 ASCRS survey, what percentage of cataract surgeons were using intracameral (IC) antibiotic prophylaxis? (00:12)
  2. Which antibiotics were used? (01:02)
  3. How do these findings compare to those of the 2014 and 2007 surveys? (02:18)
  4. What reasons were given for not using IC antibiotics? (03:15)
  5. What can be done to increase the global use of IC antibiotic prophylaxis? (04:00)

Speaker Disclosure: David Chang has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of ASCRS 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup